File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1177/1759720X20962618
- Scopus: eid_2-s2.0-85092600628
- PMID: 33133244
- WOS: WOS:000581609100001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis
Title | Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis |
---|---|
Authors | |
Keywords | biologics community-acquired pneumonia smoking Spondyloarthritis steroid |
Issue Date | 2020 |
Publisher | SAGE Publications (UK and US): Creative Commons Attribution. The Journal's web site is located at https://journals.sagepub.com/home/taba |
Citation | Therapeutic Advances in Musculoskeletal Disease, 2020, v. 12 How to Cite? |
Abstract | Aims: To compare the risk of community-acquired pneumonia (CAP) requiring hospitalization in spondyloarthritis (SpA) and non-specific back pain (NSBP), and to identify the risk factors for CAP in SpA. Methods: A total of 2984 patients with SpA from 11 rheumatology centers and 2526 patients with NSBP from orthopedic units were reviewed from the centralized electronic database in Hong Kong. Incidence of CAP requiring hospitalization and demographic data including age, gender, smoking and drinking status, use of sulfasalazine, individual biological-disease modifying anti-rheumatic drugs (DMARDs) used, micro-organisms, other immunosuppressants or immunosuppressive states, use of steroid for more than ½ year, and co-morbidities were identified. Risks of CAP in SpA were compared with those in NSBP using propensity score regression method. Multivariate Cox regression model was used to identify the risk factors in SpA. Results: CAP requiring hospitalization was found in 183 patients with SpA and 138 patients with NSBP. Increased risk for CAP was found in the following groups with SpA: all subgroups (hazard ratio (HR) 2.14, p < 0.001), without use of DMARDs (HR 2.64, p < 0.001), without psoriasis and not taking DMARDs (HR 2.38, p < 0.001). Infliximab (HR2.55, p = 0.04), smoking (HR 1.68, p = 0.003), comorbid psoriasis (HR 1.67, p = 0.003), and use of steroid for more than ½ year (HR 1.94, p = 0.003) were found to associate with CAP after adjustments for traditional risk factors. Conclusion: Risk of CAP is increased in patients with SpA. Our data favor universal influenza and pneumococcal vaccination programs in the population. Rheumatologists should also advise smoking cessation and avoid long term steroid therapy. © The Author(s), 2020. |
Description | Hong Kong Society of Rheumatology |
Persistent Identifier | http://hdl.handle.net/10722/289784 |
ISSN | 2023 Impact Factor: 3.4 2023 SCImago Journal Rankings: 1.061 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, HY | - |
dc.contributor.author | Tam, LS | - |
dc.contributor.author | Chan, SCW | - |
dc.contributor.author | Cheung, JPY | - |
dc.contributor.author | Wong, PY | - |
dc.contributor.author | Ciang, CO | - |
dc.contributor.author | Ng, HY | - |
dc.contributor.author | Law, MY | - |
dc.contributor.author | Lai, TL | - |
dc.contributor.author | Wong, CH | - |
dc.date.accessioned | 2020-10-22T08:17:26Z | - |
dc.date.available | 2020-10-22T08:17:26Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Therapeutic Advances in Musculoskeletal Disease, 2020, v. 12 | - |
dc.identifier.issn | 1759-720X | - |
dc.identifier.uri | http://hdl.handle.net/10722/289784 | - |
dc.description | Hong Kong Society of Rheumatology | - |
dc.description.abstract | Aims: To compare the risk of community-acquired pneumonia (CAP) requiring hospitalization in spondyloarthritis (SpA) and non-specific back pain (NSBP), and to identify the risk factors for CAP in SpA. Methods: A total of 2984 patients with SpA from 11 rheumatology centers and 2526 patients with NSBP from orthopedic units were reviewed from the centralized electronic database in Hong Kong. Incidence of CAP requiring hospitalization and demographic data including age, gender, smoking and drinking status, use of sulfasalazine, individual biological-disease modifying anti-rheumatic drugs (DMARDs) used, micro-organisms, other immunosuppressants or immunosuppressive states, use of steroid for more than ½ year, and co-morbidities were identified. Risks of CAP in SpA were compared with those in NSBP using propensity score regression method. Multivariate Cox regression model was used to identify the risk factors in SpA. Results: CAP requiring hospitalization was found in 183 patients with SpA and 138 patients with NSBP. Increased risk for CAP was found in the following groups with SpA: all subgroups (hazard ratio (HR) 2.14, p < 0.001), without use of DMARDs (HR 2.64, p < 0.001), without psoriasis and not taking DMARDs (HR 2.38, p < 0.001). Infliximab (HR2.55, p = 0.04), smoking (HR 1.68, p = 0.003), comorbid psoriasis (HR 1.67, p = 0.003), and use of steroid for more than ½ year (HR 1.94, p = 0.003) were found to associate with CAP after adjustments for traditional risk factors. Conclusion: Risk of CAP is increased in patients with SpA. Our data favor universal influenza and pneumococcal vaccination programs in the population. Rheumatologists should also advise smoking cessation and avoid long term steroid therapy. © The Author(s), 2020. | - |
dc.language | eng | - |
dc.publisher | SAGE Publications (UK and US): Creative Commons Attribution. The Journal's web site is located at https://journals.sagepub.com/home/taba | - |
dc.relation.ispartof | Therapeutic Advances in Musculoskeletal Disease | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | biologics | - |
dc.subject | community-acquired pneumonia | - |
dc.subject | smoking | - |
dc.subject | Spondyloarthritis | - |
dc.subject | steroid | - |
dc.title | Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis | - |
dc.type | Article | - |
dc.identifier.email | Chung, HY: jameschy@hku.hk | - |
dc.identifier.email | Cheung, JPY: cheungjp@hku.hk | - |
dc.identifier.authority | Chung, HY=rp02330 | - |
dc.identifier.authority | Cheung, JPY=rp01685 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1177/1759720X20962618 | - |
dc.identifier.pmid | 33133244 | - |
dc.identifier.pmcid | PMC7576917 | - |
dc.identifier.scopus | eid_2-s2.0-85092600628 | - |
dc.identifier.hkuros | 317582 | - |
dc.identifier.volume | 12 | - |
dc.identifier.isi | WOS:000581609100001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1759-720X | - |